Nutriband Inc. has announced amendments to its Articles of Incorporation, as approved by the Board of Directors on July 9, 2025. The company will introduce a new series of non-voting shares of Preferred Stock, known as Series A Convertible Preferred Stock, with a par value of $0.001 per share. A total of 2,788,678 shares of Series A Preferred Stock have been authorized. Additionally, a preferred stock dividend will be issued, granting shareholders one share of Series A Preferred Stock for every four shares of common stock held. The conversion of Series A Preferred Stock into common stock will be possible after the commercial approval of the company's transdermal pharmaceutical products by the FDA.